Published in JAMA on May 21, 1997
Pathophysiology of sepsis. Am J Pathol (2007) 3.19
Into the eye of the cytokine storm. Microbiol Mol Biol Rev (2012) 2.58
Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit Care Med (2013) 1.94
Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev (2013) 1.72
Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun (1998) 1.64
Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis (2005) 1.47
Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med (2013) 1.42
Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol (2007) 1.42
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol (2011) 1.36
The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med (2014) 1.30
Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest (1998) 1.24
Animal models of sepsis. Virulence (2013) 1.22
Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun (1998) 1.19
Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov (2009) 1.14
Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice. Am J Physiol Renal Physiol (2009) 1.08
Sedation improves early outcome in severely septic Sprague Dawley rats. Crit Care (2009) 1.07
PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis (1999) 1.01
Sepsis, complement and the dysregulated inflammatory response. J Cell Mol Med (2009) 1.00
Is there value in plasma cytokine measurements in patients with severe trauma and sepsis? Methods (2013) 0.93
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit Care (2005) 0.93
Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis. Infect Immun (2011) 0.93
T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression. Crit Rev Immunol (2013) 0.91
Detrimental role of CC chemokine receptor 4 in murine polymicrobial sepsis. Infect Immun (2008) 0.89
Cytokines and the early vein graft: strategies to enhance durability. J Vasc Surg (2007) 0.88
Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both? Curr Heart Fail Rep (2015) 0.84
Suppression of endotoxin- and staphylococcal exotoxin-induced cytokines and chemokines by a phospholipase C inhibitor in human peripheral blood mononuclear cells. Clin Diagn Lab Immunol (2001) 0.82
Emerging therapeutic targets of sepsis-associated acute kidney injury. Semin Nephrol (2015) 0.81
Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis. Eur J Clin Microbiol Infect Dis (2003) 0.81
Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. Pharmacol Res (2016) 0.79
Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? Ann Rheum Dis (1999) 0.77
Optimal antibiotic treatment in severe pneumococcal pneumonia--time for real answers. Eur J Clin Microbiol Infect Dis (2005) 0.76
Protective Effects of Huang-Lian-Jie-Du-Tang against Polymicrobial Sepsis Induced by Cecal Ligation and Puncture in Rats. Evid Based Complement Alternat Med (2013) 0.76
Sepsis: clinical dilemmas. Yale J Biol Med (2000) 0.76
TNF-alpha and shear stress-induced large artery adaptations. J Surg Res (2007) 0.75
Decreased Graft Survival in Liver Transplant Recipients of Donors with Positive Blood Cultures: A review of the UNOS dataset. Transpl Int (2016) 0.75
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis. Chin Med J (Engl) (2017) 0.75
Elevated cardiac troponins in setting of systemic inflammatory response syndrome, sepsis, and septic shock. ISRN Cardiol (2013) 0.75
Anti-TNFα Therapy in Inflammatory Lung Diseases bn. Pharmacol Ther (2017) 0.75
Sepsis Reconsidered: Identifying novel metrics for behavioral landscape characterization with a high-performance computing implementation of an agent-based model. J Theor Biol (2017) 0.75
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature (1993) 7.10
Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell (1993) 5.37
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell (1995) 5.08
Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell (1990) 4.58
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 3.89
Studying single living cells and chromosomes by confocal Raman microspectroscopy. Nature (1990) 3.88
CD14 is a pattern recognition receptor. Immunity (1994) 3.79
Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A (1990) 3.59
Unidentified gram-negative rod infection. A new disease of man. Ann Intern Med (1977) 3.53
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature (2002) 3.10
Nocardiosis: updated clinical review and experience at a tertiary center. Infection (2010) 3.01
Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun (1994) 2.92
Atracurium is associated with postoperative residual curarization. Br J Anaesth (2002) 2.83
Natural history of aortic valve endocarditis in rats. Infect Immun (1982) 2.74
Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med (1993) 2.67
Electrical properties of bimolecular phospholipid membranes. Biochim Biophys Acta (1967) 2.47
Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest (1998) 2.39
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis (1990) 2.36
Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J Infect Dis (1983) 2.35
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med (1999) 2.35
Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis (1993) 2.35
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother (2000) 2.27
A MEASURE-THEORETIC COMPUTATIONAL METHOD FOR INVERSE SENSITIVITY PROBLEMS I: METHOD AND ANALYSIS. SIAM J Numer Anal (2011) 2.27
Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor. Lancet (1973) 2.25
Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost (2010) 2.19
Prolactin-dependent rat mammary cancer: a model for man? Trans Assoc Am Physicians (1969) 2.15
Adult liver transplantation and abnormalities of splanchnic veins: experience in 53 patients. Transpl Int (1997) 2.14
Direct determination of the structure of barium stearate multilayers by x-ray diffraction. Biophys J (1972) 2.11
Silver coated materials for external fixation devices: in vitro biocompatibility and genotoxicity. Biomaterials (2002) 1.99
Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit Care Med (2002) 1.98
Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med (1994) 1.93
Nonresonant confocal Raman imaging of DNA and protein distribution in apoptotic cells. Biophys J (2003) 1.92
Human TNF mutants with selective activity on the p55 receptor. Nature (1993) 1.91
X-ray diffraction studies of lecithin bimolecular leaflets with incorporated fluorescent probes. Proc Natl Acad Sci U S A (1972) 1.89
On the location of I-anilino-8-naphthalene-sulfonate in lipid model systems. An x-ray diffraction study. Biochim Biophys Acta (1971) 1.89
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med (2001) 1.88
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother (2002) 1.88
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol (2001) 1.88
Medical applications of Raman spectroscopy: from proof of principle to clinical implementation. Biopolymers (2002) 1.86
In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles. J Invest Dermatol (2001) 1.84
Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol (1992) 1.82
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med (1994) 1.81
Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine (1990) 1.72
Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab (1990) 1.71
Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol (1996) 1.69
Mortality among homeless people with schizophrenia in Sydney, Australia: a 10-year follow-up. Acta Psychiatr Scand (2001) 1.68
Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit Care Med (1998) 1.65
Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis (1989) 1.64
Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology (1992) 1.63
Prospective study of the performance of vibrational spectroscopies for rapid identification of bacterial and fungal pathogens recovered from blood cultures. J Clin Microbiol (2003) 1.63
Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother (1995) 1.63
T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation. Eur J Immunol (1986) 1.62
Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol (1999) 1.62
Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother (2000) 1.61
Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis (2010) 1.60
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.58
Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. J Biol Chem (1991) 1.57
Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS (1994) 1.55
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother (2003) 1.55
Molecular and phenotypic mapping of genes controlling seed coat pattern and color in common bean (Phaseolus vulgaris L.). J Hered (2002) 1.54
Increased rigidity and priming of polymorphonuclear leukocytes in sepsis. Am J Respir Crit Care Med (1999) 1.54
Risk factors for development of hemolytic uremic syndrome during shigellosis. J Pediatr (1987) 1.53
Caspofungin--a new therapeutic option for oropharyngeal candidiasis. Clin Microbiol Infect (2004) 1.52
Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis (1985) 1.52
Typhoid fever. Studies of blood coagulation, bacteremia, and endotoxemia. Arch Intern Med (1978) 1.52
Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem (1993) 1.51
Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med (1997) 1.50
Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis (1991) 1.50
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med (1998) 1.50
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother (1990) 1.49
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis (2005) 1.47
Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet (1985) 1.47
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother (2001) 1.47
RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38alpha mitogen-activated protein kinase (p38alphaMAPK). J Biol Chem (1998) 1.46
Decreased mortality rate and length of hospital stay in surgical intensive care unit patients with successful selective decontamination of the gut. Crit Care Med (1993) 1.46
Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg (1995) 1.46
Differential prognosis of gram-negative versus gram-positive infected and sterile pancreatic necrosis: results of a randomized trial in patients with severe acute pancreatitis treated with adjuvant selective decontamination. Clin Infect Dis (1997) 1.45
Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol (1995) 1.45
Septicemia caused by Capnocytophaga in a granulocytopenic patient with glossitis. Arch Intern Med (1980) 1.44
Nonresonant Raman imaging of protein distribution in single human cells. Biopolymers (2003) 1.44
Typhoid fever complicated by intestinal perforation: a persisting fatal disease requiring surgical management. Rev Infect Dis (1985) 1.44
Patient-to-patient spread of a single strain of Corynebacterium striatum causing infections in a surgical intensive care unit. J Clin Microbiol (1996) 1.44
A WBAN System for Ambulatory Monitoring of Physical Activity and Health Status: Applications and Challenges. Conf Proc IEEE Eng Med Biol Soc (2005) 1.43
Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis (1995) 1.43